In 2024, The Ganesha Lab expanded its influence through partnerships, program enhancements, and portfolio growth. With a vision to empower biotech startups and position them for global Impact, the company provided strategic guidance and critical resources to help companies scale their solutions and reach international markets.

The BIGinBIO Program 2024 drew over 120 applicants from 11 countries, underscoring the widespread interest in Latin American biotech innovation. Following a rigorous selection process, five promising startups joined the 9th Cohort to participate in an intensive six-month scale-up program. These companies included TELL, which pioneers early detection of neurodegenerative disorders using speech-based technology; Patagon Fiber, offering sustainable, zero-emission, bacteria-derived alternatives to toxic inks; Nanotransfer, advancing delivery systems to make life-changing gene therapies accessible to all; Eywa, enabling global research to create more effective and lasting mental health treatments; and Amplify Dynamics, delivering ultra-pure lipid nanoparticles to accelerate the development of life-saving therapies. The program equipped these startups with critical tools, mentorship, and exposure to global investors.

The Ganesha Lab’s portfolio companies also celebrated significant milestones in 2024:

• Luyef Biotechnologies secured $1.25 million in grants to advance sustainable cultivated meat technologies, furthering its mission to revolutionize alternative protein production.
• Unibaio won the Grow-NY competition, highlighting its agricultural biotech innovations and showcasing its ability to impact sustainable farming practices. As a result of this recognition, Unibaio was granted one million dollars.
• metaBIX Biotech expanded into the Brazilian market, strengthening its presence in agricultural biotechnology and opening new growth avenues.
• EYWA Biotech earned second place at RESI Boston, demonstrating its potential to revolutionize psychedelic compound development and supporting mental health treatments through cutting-edge science. Additionally, EYWA Biotech was named as one of the companies to watch in 2025.

The Ganesha Lab forged key alliances, including a partnership with Merken Biotech, to drive collaborative efforts in Latin American biotechnology. This partnership is focused on scaling innovative solutions and expanding commercialization opportunities, reflecting a broader effort to build a strong biotech ecosystem in the region.

The Latin American Biotech ecosystem is brimming, and our presence is critical to capture the best opportunities while impacting the ecosystem with our knowledge. Therefore, the organization actively participated in global biotech events, strengthening its network and positioning Latin American startups on the world stage.

Events like JP Morgan Week, RESI Boston, DeepTech Summit in Brazil,  LimaTechWeek, OktoberINVESTfest and Open Innovation Summit in Bogotá provided platforms for startups and the company to connect with investors, researchers, and strategic partners. These engagements not only validated the potential of participating startups but also opened doors to funding and collaboration opportunities.

The Ganesha Lab also welcomed a new Board of Directors to strengthen its leadership and governance. The board now includes Christoph Schiess, Alejandra Pérez, Roberto Braga-Mendes, Nicolas del Campo and Markus Schreyer, bringing extensive expertise in biotech, investment, and entrepreneurship. Their combined insights and strategic vision will guide The Ganesha Lab in advancing its mission and scaling its impact globally.

Building on the successes of 2024, The Ganesha Lab is set to scale new heights in 2025. Plans include onboarding additional high-potential startups, enhancing mentorship programs, expanding into new biotech ecosystems across Latin America and launching a new initiative aimed at expanding into Europe—an ambitious and highly promising market.

As it continues to transform science into good businesses, The Ganesha Lab reaffirms its commitment to shaping the future of biotechnology. With a strong focus on sustainability, scalability, and impact, the organization looks forward to supporting even more groundbreaking innovations in the years ahead. The achievements of 2024 have set a solid foundation, demonstrating the power of collaboration, expertise, and vision in propelling biotech startups toward global success.